AGPAT5

1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon · Q9NUQ2 · AGPAT5 on Sugi Atlas →

0 patent compounds predicted against AGPAT5, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to AGPAT5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Omega 3 and Ischemic Stroke; Fish Oil as an Option PHASE4UNKNOWN
Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging PHASE4COMPLETED
Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate PHASE2/PHASE3WITHDRAWN
Toxicity and Efficacy Evaluation of Topical Minoxidil in Acne Vulgaris PHASE1/PHASE2UNKNOWN
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease PHASE2COMPLETED
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis PHASE2UNKNOWN
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides PHASE1COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers PHASE1COMPLETED
RCDP Natural History Study nanUNKNOWN
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity. nanCOMPLETED
A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism nanCOMPLETED
the Role of plin5 in the Development of Nonalcoholic Fatty Liver Disease. nanUNKNOWN
Epidemiology of Atherosclerosis nanCOMPLETED
Evaluation of Botanicals for Mechanisms Related to Appetite and Fat Metabolism nanCOMPLETED
Structural Network on Prostate Cancer in the French Greater West Region nanCOMPLETED
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children nanWITHDRAWN
A Study on Risk Mutations of Vulnerability Genes of Schizophrenia nanUNKNOWN
Gene Expression in Obesity and Insulin Resistance nanCOMPLETED
Triglyceride-rich LIPoproteins and INflammatory Cytokines After Oral FAT Loading as Potential Early Biomarkers of the Risk of Progression Towards DIABETES and Development of Complications. LIPINFAT Diabetes Study. nanRECRUITING
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients nanCOMPLETED
Plasma Mannose Associated Parameter Levels in Nondiabetic Coronary Artery Disease nanCOMPLETED
Choline to Improve Malnutrition and Enhance Cognition nanRECRUITING
Plant-based Diets and Body Weight and Selected Metabolic Parameters Management in Obese Patients. nanCOMPLETED
Genetic Determinants:Low HDL, High Triglycerides, Obesity nanCOMPLETED
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes nanCOMPLETED
Familial Partial Lipodystrophy Study nanCOMPLETED
Genetic and Environmental Determinants of Triglycerides (GOLDN) nanCOMPLETED
Genetic Origin of Lipid Disorders nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a AGPAT5 binder may also engage these)

ProteinNameSimilarity
Q9D1E8 0.988 Q9D1E8 →
Q924S1 0.983 Q924S1 →
Q8K4X7 0.979 Q8K4X7 →
Q5R757 0.974 Q5R757 →
Q9NRZ5 0.970 Q9NRZ5 →
Q4R581 0.970 Q4R581 →
Q9D517 0.969 Q9D517 →
Q5RA57 0.968 Q5RA57 →
Q5E9R2 0.968 Q5E9R2 →
Q9D850 0.967 Q9D850 →
Q0VCR6 0.967 Q0VCR6 →
Q96MH6 0.965 Q96MH6 →
GNPAT Dihydroxyacetone phosphate acyltransferase 0.960 landscape →
G5AY81 0.960 G5AY81 →
G1SPE9 0.960 G1SPE9 →
Q9NRZ7 0.959 Q9NRZ7 →
Q9ASU1 0.959 Q9ASU1 →
K7K424 0.958 K7K424 →
Q8K3K7 0.957 Q8K3K7 →
Q9R0E0 0.957 Q9R0E0 →
Q5RF53 0.956 Q5RF53 →
O57424 0.956 O57424 →
O88693 0.956 O88693 →
A4IF87 0.956 A4IF87 →
UGCG Ceramide glucosyltransferase 0.955 landscape →
Q58E26 0.955 Q58E26 →
Q3TFD2 0.955 Q3TFD2 →
Q70VZ8 0.955 Q70VZ8 →
Q8S8S2 0.955 Q8S8S2 →
Q8L4Y2 0.954 Q8L4Y2 →